Jun 17, 2026
At the 2026 Charing Cross Symposium (CX 2026), a panel consisting of experts in the field of hemodialysis access discussed why endovascular AV fistula (endoAVF) technology initially struggled and why they believe it is now poised for renewed growth as a part of a two...
Apr 18, 2026
We are excited to announce that the abstract, The VENOS-2 Early Feasibility Study: Six-Month Outcomes of the Velocity® Percutaneous Arteriovenous Fistula System (NCT06712251) was presented by Bart Dolmatch, MD as a featured late breaking abstract at the recent SIR...
Dec 1, 2025
Los Gatos, California – December 1, 2025 – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, announced today the publication of first-in-human...
Nov 3, 2025
Rishi Razdan, MD, Medical Director of Azura Vascular Care Jacksonville in Jacksonville, Florida, presented mid-term results from the Venova Medical sponsored VENOS-2 study during the 2025 Controversies in Dialysis Access (CiDA) meeting held in Boston, Massachusetts....
Oct 15, 2024
(Los Gatos, California) – Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access today announced that it will present an oral...
Oct 15, 2024
Robert Shahverdyan, MD, from Hamburg, Germany presented one-year results from the VENOS-1 first-in-human study, which examined the VelocityTM Percutaneous Arteriovenous Fistula (pAVF) System during the recent Controversies in Dialysis Access (CiDA) meeting held in...
